Mydriasis Clinical Trial
Official title:
Randomized, Cross-Over, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution to Reverse Pharmacologically Induced Mydriasis in Normal Healthy Subjects
The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol
Randomized, 2-arm cross-over, double-masked Phase 2b study in approximately 32 healthy subjects, evaluating safety and efficacy of Nyxol in subjects with pharmacologically induced mydriasis. At the first visit subjects will be screened for study eligibility. After screening, eligible subjects will be randomized 1:1 to one of the two treatment sequences: Treatment sequence 1: Placebo (Visit 1), Nyxol (Visit 2). Treatment sequence 2: Nyxol (Visit 1), Placebo (Visit 2). Randomization will be stratified by mydriatic agent (2.5% phenylephrine or 1% tropicamide). Approximately one half of the randomized subjects will receive 2.5% phenylephrine and one half will receive 1% tropicamide. Subjects will receive their mydriatic agent 1 hour before treatment. Each subject will receive the same mydriatic agent throughout the study. At each visit, pupil diameter (PD), accommodation, near and distance visual acuity (VA) and redness in each eye will be measured before (-1 hour/baseline) and 1 hour after (maximum/0 minutes) the mydriatic agent instillation in each eye (i.e., right before the study treatment is administered), and at 30 minutes, 1 hour, 2 hours, 4 hours and 6 hours after treatment dosing. As needed, two hours post treatment, subjects may request the administration of Lumify® in the non-study eye. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
| Completed |
NCT02946125 -
Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil
|
Phase 2 | |
| Completed |
NCT06217796 -
Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
|
Phase 4 | |
| Completed |
NCT05134974 -
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
|
Phase 3 | |
| Completed |
NCT04620213 -
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
|
Phase 3 | |
| Completed |
NCT03751631 -
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
|
Phase 3 | |
| Completed |
NCT04907474 -
Evaluation of Pupil Dilation Speed With the MAP Dispenser
|
Phase 4 | |
| Completed |
NCT05880433 -
The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations
|
||
| Terminated |
NCT00690222 -
Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery
|
N/A | |
| Recruiting |
NCT05829122 -
Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty
|
N/A | |
| Completed |
NCT04396301 -
Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco
|
Phase 3 | |
| Completed |
NCT05223478 -
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT03751098 -
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
|
Phase 3 |